---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-024089"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T15:13:28.807891+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioCryst agrees to sell European ORLADEYO business to Neopharmed Gentili for $250M

## Summary
- Upfront cash consideration of $250M plus up to $14M in revenue milestones if achieved before Dec 31, 2032.
- Transaction expected to close in October 2025, subject to antitrust clearance and customary closing conditions.
- BioCryst will continue as exclusive supplier of ORLADEYO under a supply agreement and enter IP license, brand support, and transition services agreements.
- Sale includes all equity of BioCryst Ireland Limited, which holds European ORLADEYO assets and rights.
- The amended IP license may extend to the pediatric line extension of ORLADEYO subject to regulatory approvals.

## SEC filing metadata
- accession: 0001140361-25-024089
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000114036125024089/0001140361-25-024089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000114036125024089/ef20051351_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-024089
- JSON: https://secwatch.observer/filing/0001140361-25-024089.json
- Plain text: https://secwatch.observer/filing/0001140361-25-024089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.